Smart machine takes over weaning of lung medicine for sick newborns
NCT ID NCT06832163
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new smart device that automatically lowers the dose of inhaled nitric oxide in newborns with persistent pulmonary hypertension. The device aims to make the weaning process safer and more consistent by using a gradual, real-time reduction instead of manual step changes. Thirty infants whose families agree to participate will be enrolled to see if the smart weaning reduces oxygen drops and shortens treatment time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- inhaled nitric oxide delivered via a smart closed-loop device
- What this could lead to
- If successful, this could establish a safer, more standardized way to wean newborns off inhaled nitric oxide, reducing manual errors and staff workload.
- What could go wrong
- This is a small, early-stage study with only 30 participants, and the smart weaning feature has not been tested clinically before. It may not show clear benefits over current methods.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INHALED NITRIC OXIDE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Fudan University
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.